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T-bet expression in eosinophilic
esophagitis versus
gastroesophageal reflux diseaseTo the Editor:
Eosinophilic esophagitis (EoE) is a clinicopathological condi-
tion characterized by symptoms of esophageal dysfunction and
dense eosinophil infiltration of the esophageal epithelium. The
current diagnostic metric requires 15 eosinophils (eos) per hpf in
at least 1 mucosal biopsy specimen following 6 to 8 weeks of
treatment with high-dose proton pump inhibitor (PPI).1 Although
this histologic threshold distinguishes most subjects with EoE,
several shortcomings exist including the following: (1) eosino-
philia may underestimate the extent of eosinophil activity; (2)
some patients with gastroesophageal reflux disease (GERD)
may have distal esophageal eosinophilia exceeding 15 eos/hpf;
and (3) patients often require more than 1 biopsy to determine
the underlying diagnosis and establish appropriate treatment.Recent evidence suggests that EoE and proton pump inhibitor-
responsive esophageal eosinophilia (PPI-REE) have a similar
transcriptome2 and are phenotypically indistinguishable.3 Novel
histologic biomarkers may further aid in distinguishing causes
of esophageal eosinophilia.
Characterizations of mucosal inflammatory responses in EoE
and PPI-REE describe a TH2-predominant pattern with
overexpression of TH2-associated genes.
4 In EoE, IL-5 and
IL-13 levels are associated with eotaxin-3 expression, which
likely drives eosinophil recruitment. In contrast, esophageal
biopsies from patients with GERD are more commonly
associated with a TH1 phenotype defined by increased mRNA
expression of IL-1b, IL-8, and IFN-g.5
T-bet and GATA-3 are transcriptional regulators that drive
differentiation of TH0 CD4
1 lymphocytes to TH1 and TH2
lineages, respectively. We previously demonstrated the utility of
characterizing tissue-specific immune polarization using
immunohistochemistry-based assessments of GATA-3 and T-bet
in bladder cancer.6 Given its role in TH2-associated inflammation,
we hypothesized that GATA-3 expression would be increased in
EoE and PPI-REE and that the ratio of GATA-3/T-bet expression
would differentiate these individuals from subjects with GERD.
We performed a retrospective, case-control study of children
characterized clinically as having EoE (n 5 24), PPI-REE
(n 5 10), or GERD (n 5 28) and as controls (n 5 32). Subjects
diagnosed with EoEwere treated with an elimination diet (n5 7),
swallowed topical steroids (n 5 12), or a combination of
elimination diet and swallowed topical steroids (n5 5) and those
with PPI-REE were treated with high-dose PPI (2 mg/kg/d). All
subjects with EoE and PPI-REE demonstrated histologic
resolution of esophageal eosinophilia (<15 eos/hpf) after 6 to
8 weeks of treatment, respectively.
Tissue sections from active and matched posttreatment
biopsies were assessed with hematoxylin and eosin, and
immunohistochemical staining for T-bet and GATA-3 was
performed. Slides stained for T-bet and GATA-3 were digitized
and staining of the epithelial layer was quantified (see Fig E1 in
this article’s Online Repository at www.jacionline.org).
A nuclear algorithm was used to identify T-bet1 and GATA-
31 cells. The number of positive cells was divided by the total
area of esophageal epithelium analyzed in order to normalize
the number of T-bet1 and GATA-31 cells/mm.2 Polarization
of the immune microenvironment was assessed by the GATA-
31 cells/mm2/T-bet1 cells/mm2 (G/T) ratio. Details regarding
the study population, methods for T-bet/GATA-3 staining/
quantification, and statistical analysis are detailed in this article’s
Online Repository at jacionline.org.
Table E1 in this article’s Online Repository at www.jacionline.
org details the demographic and clinical characteristics of the
study population. Staining for GATA-3 and T-bet by immunohis-
tochemistry is shown in Fig 1. In comparison to GERD, subjects
with active EoE demonstrated increased GATA-31 cells/mm2
(median, 2.81 vs 8.46 cells/mm2; P < .0001; area under the curve,
0.88; 95% CI, 0.78-0.97) and T-bet1 cells/mm2 (median, 7.12 vs
12.01 cells/mm2; P < .0001; area under the curve, 0.79; 95% CI,
0.66-0.93) (see Fig 2, B, C, and F). No statistical differences in
GATA-3 and T-bet expression were found between subjects
with active EoE and PPI-REE. GATA-3 and T-bet expression
was also significantly elevated in subjects with active EoE
compared with healthy controls. Following treatment, GATA-3
and T-bet expression decreased significantly in subjects with
FIG 1. Subjects with EoE have increased GATA-3 and T-bet expression. Immunohistochemistry stains for
GATA-3 and T-bet in the same subject with active and inactive EoE.
FIG 2. GATA-31 cells and T-bet1 cells are increased in subjects with EoE, correlate with esophageal
eosinophilia, and decrease in response to treatment. Peak esophageal eosinophil counts are shown in A.
Expression of GATA-3 (B) and T-bet (C) is increased in EoE relative to GERD and health controls. Similar trends
were noted for subjects with PPI-REE but these did not reach statistical significance. The G/T ratio does not
distinguish subjects with EoE or PPI-REE (D). GATA-3 and T-bet correlate with eos/hpf (E). Receiver-
operating characteristic curves for eos/hpf, GATA-31 cells/mm2, and T-bet1 cells/mm2 suggest that GATA-3
and T-bet expressions may serve as histologic biomarkers that differentiate active EoE from GERD (F).
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observed for subjects with PPI-REE, such that those with inactive
EoE/PPI-REE were indistinguishable from those with GERD and
control subjects based on nuclear transcription factor expression.
No significant differences were observed between groups for the
G/T ratio (see Fig 2, D).
While EoE has been defined as a type 2 cytokine-mediated
disease, we observed similar increases in GATA-31 and
T-bet1 cells in subjects with active EoE and PPI-REE.
Expression of both markers was associated with active disease
and the G/T cellular ratio did not serve as a histologic marker of
EoE or PPI-REE. The observed differences were almost
identical when the relative percentages of GATA-31 and
T-bet1 cells were compared among groups (see Fig E2 in
this article’s Online Repository at www.jacionline.org),
suggesting tissue polarization in addition to cellular
infiltration. Our observations corroborate earlier findings5
suggesting that EoE and PPI-REE share a common
pathophysiology and that PPIs, topical corticosteroids, and
dietary elimination each result in decreased GATA-3
expression. The significance of increased T-bet expression is
unclear but suggests that a mixed TH2/TH1 inflammatory
infiltrate is associated with active disease. Consistent with
this finding, others have demonstrated increased expression
of TH1 cytokines (IFN-g
7 and TNF-a8) in EoE.
We acknowledge the limitation that this is a retrospective,
single-center study of pediatric subjects; therefore, the results
cannot be generalized to adults. Second, immunohistochemical
assessments were performed on only a single biopsy specimen
from each endoscopy; therefore, it is possible that the immune
polarization described is confined to areas of maximum
eosinophil infiltrate. Although GATA-3 and T-bet expression
was similar in EoE and PPI-REE, we did not examine a sufficient
number of subjects with PPI-REE in order to observe statistical
differences between groups or following treatment for subjects
with PPI-REE. Finally, we did not perform dual staining to
ensure that the cells positive for GATA-3 and T-bet were CD41
helper T cells; therefore, these transcription factors may be
expressed by other cell types, including innate lymphoid cells,
regulatory T cells,9 and natural killer cells (see Fig E3 in this
article’s Online Repository at www.jacionline.org). However,
these limitations are balanced by a number of strengths
including detailed clinical information, automated assessment
of GATA-3/T-bet expression, and blinded analysis of tissue
samples.
In summary, we observed that subjects with EoE have
increased GATA-3 and T-bet expression when compared with
subjects with GERD and healthy controls. Similar trends were
noted for subjects with PPI-REE. Automated assessment of the
GATA-3 and T-bet expression may be a useful strategy to
distinguish subjects with EoE/PPI-REE and GERD; moreover,
these markers may also be useful in assessing treatment
response.
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https://doi.org/10.1016/j.jaci.2017.12.993High number of early respiratory
infections in association with
allergic sensitization to mold
promotes childhood asthmaTo the Editor:
The relationships among early life respiratory infections,
aeroallergen sensitization, and subsequent development of
childhood asthma is unclear. To examine the effects of respiratory
infections and allergic sensitization on asthma development, data
from the Cincinnati Childhood Allergy and Air Pollution Study
(CCAAPS) birth cohort were evaluated.
METHODS
Study Population
Pediatric subjects (aged 1-18 years) were retrospectively identified at the
Children’s Hospital of Colorado from 2006 to 2016. This study was approved
by the Colorado Multiple Institutional Review Board (institutional review
board approval no. 07-0888).
Case definitions, clinical data, and biospecimen
collection
Diagnosis of active EoE was defined by consensus guidelines.E1 Subjects
with PPI-REE were treated with high-dose PPI for at least 8 weeks and had
less than 15 eos/hpf on repeat endoscopic biopsy. Subjects with GERD dis-
played symptoms consistent with reflux as defined by a pediatric gastroenter-
ologist or had an abnormal pH/impedance study. Control subjects had
gastrointestinal symptoms necessitating an upper endoscopy with normal his-
tology (0 eos/hpf). Clinical data were collected through retrospective chart re-
view. Asthma, eczema, seasonal allergies, and IgE-mediated food allergies
were determined by clinical history as documented in the medical record. Tis-
sue analysis was performed using paraffin-embedded esophageal tissue sec-
tions from the Children’s Hospital of Colorado. Esophageal eosinophil
counts were quantified by a pediatric pathologist. Study personnel were
blinded as to case/control status during sample analysis.
Immunohistochemical staining of GATA-3 and
T-bet
Tissue sectioning and immunohistochemical staining were performed at
the Pathology Research Core (Mayo Clinic, Rochester, Minn) using the Leica
Bond RX stainer (Leica Biosystems, Nussloch, Germany). Five-micron
formalin-fixed, paraffin-embedded (FFPE) tissue sections were treated with
Bond Epitope Retrieval 1 (Citrate; Leica Biosystems, Newcastle, UK) for
20 minutes and Protein Block Serum-Free (Dako, Carpinteria, Calif) for
5 minutes. GATA-3 (clone L50-823, Biocare Medical, Pacheco, Calif) and
T-bet (SC-21003, Santa Cruz Biotech, Dallas, Tex) were diluted in Antibody
Diluent, Background Reducing (Dako, Carpinteria, Calif) at 1:400 and 1:150,
respectively, and applied to tissue for 15 minutes.
The detection system used was Bond Polymer Refine Detection System
(Leica Biosystems). This system includes the hydrogen peroxidase block,
postprimary and polymer reagent, 39-diaminobenzidine (DAB), and
hematoxylin. Immunostaining visualization was achieved by incubating the
slides for 10 minutes in DAB and DAB buffer (1:19 mixture) from the Bond
Polymer Refine Detection System. To this point, slides were rinsed between
steps with 13 Bond Wash Buffer (Leica Biosystems). Slides were counter-
stained for 5minutes using Schmidt hematoxylin andmolecular biology grade
water (1:1 mixture), followed by several rinses in 13 Bond wash buffer and
distilled water; this is not the hematoxylin provided with the Refine kit. Once
the immunohistochemistry process was completed, slides were removed from
the stainer and rinsed in tap water for 5 minutes. Slides were dehydrated in
increasing concentrations of ethyl alcohol and cleared in 3 changes of xylene
before permanent coverslipping in xylene-based medium.
Image analysis
Tissue sections were digitized (Aperio AT Turbo; Leica Biosystems,
Buffalo Grove, Ill) and analyzed using Aperio ImageScope software (version
11.2.0.780; Aperio Technologies, Vista, Calif). Serial sections of esophageal
biopsies where themaxiumum eosinophil focus was located were analyzed for
each subject. The submucosal layer was outlined to subtract it from analysis
(see Fig E1). Image analysis using a nuclear algorithmwas used to quantify the
cells staining positive for T-bet and GATA-3. Only those nuclei that stained
strongly or moderately positive according to the algorithm were considered
positive.
Statistical analysis
Clinical characteristics of the cases and controls were summarized with
descriptive statistics. Baseline comparisons of median eos/hpf, GATA-31
cells/mm2, T-bet1 cells/mm2, and G/T ratios were made with a Mann-
Whitney test. Paired comparisons of G/T ratios pretreatment and posttreat-
ment (subjects with EoE and PPI-REE) were performed using a Wilcoxon
matched-pairs signed-rank test. Spearman rho values were used to assess cor-
relations between eos/hpf and GATA-31 cells/mm2 or T-bet1 cells/mm2. Sta-
tistical comparisons and plots were made with GraphPad Prism (version 7.00
for Windows; GraphPad software, San Diego, Calif).
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FIG E1. Image analysis of GATA-3/T-bet expression in the esophageal epithelium is an automated
assessment of immune polarization. The submucosal layer was outlined to exclude it from analysis. DAB
stains for GATA-3 of the esophageal epithelium are shown at low power (A) and high power (B). Image anal-
ysis software using a nuclear algorithm quantifies the cells staining strongly positive (red), moderately pos-
itive (orange), and weakly positive (yellow) for GATA-3. Corresponding images are shown in C and D. The
number of cells was divided by the epithelial area (mm2) analyzed. Cells staining weakly positive were not
considered positive in the data analysis.
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FIG E2. %GATA1 (A) and %T-bet1 (B) cells are increased in active EoE relative to GERD and controls and
decrease in response to treatment similar to the number of GATA-31 and T-bet1 cells when analyzed per
unit area (mm2). GATA-31 and T-bet1 cells were quantified as a percentage of the total number of nucle-
ated cells present.
J ALLERGY CLIN IMMUNOL
MAY 2018
1921.e3 LETTERS TO THE EDITOR
FIG E3. GATA-3 (probe set 209604_s_at, panel A) and TBX21 (encoding T-bet, probe set 220684_at, panel B)
expression patterns in human immune cells. Data publicly accessible from the Immunological Genome
Database at http://www.immgen.org/databrowser. DC, Dendritic cell; NK, natural killer.
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TABLE E1. Baseline characteristics of the study population
Characteristic GERD (n 5 28) PPI-REE (n 5 9) EoE cases (n 5 24) Controls (n 5 32)
Age (y), mean 6 SD 3.7 6 2.1 7.6 6 5.5 4.0 6 2.8 12.0 6 4.9
Sex: male, n (%) 21 (75) 8 (89) 22 (92) 13 (41)
White, n (%) 23 (82) 8 (89) 23 (96) 19 (59)
Atopic conditions, n (%)
Asthma 13 (46) 4 (44) 10 (42) 0 (0)
Eczema 4 (14) 2 (22) 11 (46) 2 (6)
Seasonal allergies 12 (43) 2 (22) 11 (46) 1 (3)
Food allergies 4 (14) 3 (33) 14 (58) 1 (3)
Peak eosinophil counts, mean eos/hpf 6 SD
Baseline 0.9 6 2.1 53.9 6 45.0 54 6 33.2 0
Posttreatment — 1.9 6 2.9 2.2 6 3.3 —
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